InflaRx N.V. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for IFRX, updated each market day.
IFRX AI Sentiment
AI sees no strong directional signal for InflaRx N.V. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About InflaRx N.V. Common Stock
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Exchange
Market Cap
$74,461,644
Cap Tier
Employees
65
Listed Since
Nov. 8, 2017
Website
IFRX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
IFRX Volatility
InflaRx N.V. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
